Get solid data to base decisions on

Contract research services within Diabetic Complications

Gubra has long-standing experience of conducting preclinical diabetic nephropathy studies in a variety of different rodent models of both type 1 and type 2 diabetes. We complement the models with novel histology imaging endpoints and biomarker endpoints.

Gubra offers consultancy and preclinical models within cardiovascular disease including heart failure and atherosclerosis.

Our scientific expertise within diabetes, combined with our experience within micro- and macrovascular models, provide solid data on which to base decisions.

We offer:

Diabetic nephropathy models
Cardiovascular disease models (cardiomyopathy, heart failure and hypertension)
Glomerular filtration rate and metabolic caging for urine sampling
Advanced histology, image analysis and 3D imaging of heart and kidney
Continuous (24h) monitoring of heart rate and ECG
Rat echocardiography
RNA sequencing and bioinformatics

Get in touch

Please get in touch if you are interested in discussing how to get started with your study.

Niels Vrang

Co-founder, Chairman of the board
niels@gubra.dk
+45 3152 2651

Get in touch

Contact us

T1D rat DN model: Gubra Px-UNx

Novel diabetic nephropathy model displaying progressive albuminuria, glomerulosclerosis and renal fibrosis. Diabetes-induction with no side-effects from toxic compounds. The partial pancreatectomy combined with unilateral nephrectomy permits a short duration: 11 weeks

Novel Rat Model of Diabetic Nephropathy Displaying Tubular Fibrosis and Glomerular Alterations

T2D mouse DN model: db/db UNx

Refinement of the well-described db/db model of diabetic nephropathy. Unilateral nephrectomy permits shorter duration (18 weeks of age), where animals develop albuminuria and glomerular hypertrophy. Pharmacological effects quantified by advanced image analysis, stereology or 3D imaging

Unbiased Stereological Quantification of Key Features of Diabetic Nephropathy

3D kidney imaging for assessment of glomerular number and size in a mouse model of diabetic nephropathy

Diabetic rat model with myocardial alterations

Diabetes model displaying cardiomyopathy as early as 10 weeks after diabetes-induction by partial pancreatectomy and pharmacologically induced cardiac stress. In vivo functional (echo- and electrocardiography) and histological (endomyocardial fibrosis) readouts affected.

Novel ‘Dual Hit’ Rat Model of Diabetic Cardiomyopathy

“Gubra is a highly competent partner in execution of – also more complicated – preclinical studies. The long term experience and the deep scientific competence of Gubra partners adds value to the studies and is a guaranty for trustworthy results.“

Dr. Michael Mark
Vice President | Boehringer Ingelheim

Endpoints

Imaging and iDISCO

3D imaging of whole organs allows unbiased volume determination and IHC on all glomeruli
Labelled tracers (drug compounds, endothelium-binding lectin)
Immunofluorescence (iDISCO)
After imaging, tissue can be processed for conventional histology and immunohistochemistry

Histology, stereology and image analysis

Obtain unbiased quantified tissue data

Podocyte number (WT-1)
Glomerular number and volume
Glomerulus-specific collagen IV
Tubulointerstitial fibrosis: collagen III

GFR and albuminuria

Glomerular filtration rate and urinary biomarkers

Glomerular filtration rate tracer measured a) in plasma samples or b) transcutaneously
Albumin-to-creatinine ratio and total albumin secretion
Podocyte (podocalyxin) and tubular (NGAL) injury markers measured in urine

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

info@gubra.dk
+45 3152 2650

CRO Services

Diabetes Obesity NASH

Partner Programs

Diabetes Obesity NASH

Methodology

In vivo pharmacology Histology & stereology NGS & bioinformatics Ex vivo assays Molecular pharmacology Petide chemistry

Publications

Publications

About us